Synonym
SR 43845; SR-43845; SR43845;
IUPAC/Chemical Name
(3R,4R)-4-((R)-3-(1H-imidazol-5-yl)-2-((S)-3-phenyl-2-(3-(pyridin-3-yl)propanamido)propanamido)propanamido)-5-cyclohexyl-N-((2S,3R)-1-((1,3-dihydroxy-2-methylpropan-2-yl)amino)-3-methyl-1-oxopentan-2-yl)-3-hydroxypentanamide
InChi Key
NZGWKVVFXREROW-UHFFFAOYSA-N
InChi Code
1S/C44H64N8O8/c1-4-29(2)40(43(60)52-44(3,26-53)27-54)51-39(57)23-37(55)34(20-30-12-7-5-8-13-30)49-42(59)36(22-33-25-46-28-47-33)50-41(58)35(21-31-14-9-6-10-15-31)48-38(56)18-17-32-16-11-19-45-24-32/h6,9-11,14-16,19,24-25,28-30,34-37,40,53-55H,4-5,7-8,12-13,17-18,20-23,26-27H2,1-3H3,(H,46,47)(H,48,56)(H,49,59)(H,50,58)(H,51,57)(H,52,60)
SMILES Code
O=C(CCc1cccnc1)N[C@@H](Cc2ccccc2)C(N[C@H](Cc3[nH]cnc3)C(N[C@@H]([C@H](O)CC(N[C@H](C(NC(C)(CO)CO)=O)[C@H](C)CC)=O)CC4CCCCC4)=O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
833.04
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Lacour C, Cazaubon C, Roccon A, Segondy D, Wagnon J, Nisato D. Effects of a renin inhibitor, SR 43845, and of captopril on blood pressure and plasma active renin in conscious sodium-replete macaca. J Hypertens Suppl. 1989 Apr;7(2):S33-5. PubMed PMID: 2666612.
2: Cazaubon C, Richaud JP, Nisato D. [A new method for determination of renin inhibitors]. Arch Mal Coeur Vaiss. 1990 Jul;83(8):1267-70. French. PubMed PMID: 2124466.
3: Denolle T, Luo P, Guyene TT, Cazaubon C, Sissmann J, Corvol P, Ménard J. Acute effects of a pseudo-tetrapeptide as renin inhibitor on blood pressure and renin-angiotensin system of sodium-repleted and sodium-depleted hypertensive patients. Arzneimittelforschung. 1993 Feb;43(2A):255-9. PubMed PMID: 8498973.
4: Cohen P, Simon D, Badouaille G, Mani JC, Portefaix JM, Pau B. New monoclonal antibodies directed against the propart segment of human prorenin as a tool for the exploration of prorenin conformation. J Immunol Methods. 1995 Jul 17;184(1):91-100. PubMed PMID: 7622873.
5: Lacour C, Roccon A, Cazaubon C, Richaud JP, Segondy D, Nisato D. A pharmacodynamic study of the renin inhibitor SR 43,845, administered intratracheally in conscious cynomolgus monkeys. J Hypertens Suppl. 1991 Dec;9(6):S384-5. PubMed PMID: 1819002.
